Drug Development Pipeline
Lonodelestat (formerly POL6014)
Lonodelestat is a compound designed to block the function of neutrophil elastase. Neutrophil elastase is an enzyme that plays an essential role in inflammation. When the lungs are infected with bacteria, white blood cells release enzymes, including neutrophil elastase, to fight the infection. In CF, these enzymes can result in excessive inflammation that causes damage to the lungs. Lonodelestat was studied for its potential to block the function of neutrophil elastase, minimize tissue destruction, and decrease inflammation within the CF airway.
Phase 1 studies to test the safety of this compound were completed. No further development in CF is planned at this time.
This program was sponsored by Santhera and partially funded by the Cystic Fibrosis Foundation.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Explore clinical trials
Be a part of the movement transforming the future of cystic fibrosis treatment.Learn More